Menu Search
Equities

Galmed Pharmaceuticals Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
GPH:FRA

Galmed Pharmaceuticals Ltd

Actions
  • Price (EUR)2.74
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta0.3786
Data delayed at least 15 minutes, as of Aug 29 2024 07:00 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.

  • Revenue in USD (TTM)0.00
  • Net income in USD-8.70m
  • Incorporated2013
  • Employees3.00
  • Location
    Galmed Pharmaceuticals Ltd16 Tiomkin StreetTEL AVIV-YAFO 6578317IsraelISR
  • Phone+972 36938448
  • Fax+972 36938447
  • Websitehttps://www.galmedpharma.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.